A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a <scp>T</scp>urkish cohort of patients with choroidal neovascularization secondary to <scp>AMD</scp>

Eldem, Bora; Müftüoğlu, Gülipek; Topbaş, Seyhan; Çakir, Mehmet; Kadayıfçılar, Sibel; Özmert, Emin; Bahçecioğlu, Halil; Şahin, Feride İffet; Sevgi, Serhan

doi:10.1111/aos.12540

Cited by 15 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In SALUTE study, at month 12, the median change in BCVA was similar between PRN and treat-and-extend groups (−0.12 vs. −0.18; P = 0.267). 32 The study results were significant as it highlighted potential advantages of the treat-and-extend strategy in decreasing the burden of frequent clinic visits.…”

Section: Anti-vascular Endothelial Growth Factor Agentsmentioning

confidence: 88%

“…The comparative efficacy of the anti-VEGF agents has not been evaluated using the popular treat-and-extend regimen employed in the SALUTE 32 or LUCAS 62 study. In addition, studies assessing the relative safety and efficacy of BCZ, RBZ and AFL for neovascular AMD, similar to Protocol T of Diabetic Retinopathy Clinical Research Network (for DME), 65 have not been performed [ Figure 1 ].…”

Section: Anti-vascular Endothelial Growth Factor Agentsmentioning

confidence: 99%

See 1 more Smart Citation

Management of neovascular Age-related macular degeneration: A review on landmark randomized controlled trials

Agarwal

Aggarwal

Gupta

2016

Middle East Afr J Ophthalmol

View full text Add to dashboard Cite

In the last decade, a number of prospective clinical trials with carefully designed study protocols have been conducted for the treatment of neovascular age-related macular degeneration (AMD). These landmark clinical trials such as ANCHOR and MARINA and, more recently, the Comparison of AMD Treatment Trials and VIEW studies have revolutionized the management of neovascular AMD. While AMD continues to remain a leading cause of severe visual loss worldwide, advances in pharmacotherapeutics have led to substantial improvements in the outcome of these patients. The introduction of anti-vascular endothelial growth factor agents has resulted in improvement of visual outcomes and has had a positive impact on the quality of life among elderly population. While the contemporary management of neovascular AMD has been successful in tremendously reducing the visual morbidity, the financial burden of therapy has increased exponentially. To overcome these challenges, newer pharmacologic agents are evaluated for their efficacy and safety in AMD. Ground-breaking advances in bench to bedside research have led to discovery of new pathways that appear to be viable targets for preventing visual loss in AMD. In this review, study designs and results of landmark clinical trials in AMD from the past decade have been summarized.

show abstract

Section: Anti-vascular Endothelial Growth Factor Agentsmentioning

confidence: 88%

Section: Anti-vascular Endothelial Growth Factor Agentsmentioning

confidence: 99%

Management of neovascular Age-related macular degeneration: A review on landmark randomized controlled trials

Agarwal

Aggarwal

Gupta

2016

Middle East Afr J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The median change in BCVA (logMAR) was −0.18 and −0.12 in the treat and extend and PRN groups, respectively ( p = 0.267). While the results indicate no statistically significant difference, treat and extend protocol was associated with a reduction in the number of visits [ 45 ]. TREX-AMD is another study that aimed to assess a TREX regimen for treating AMD.…”

Section: Ranibizumabmentioning

confidence: 99%

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration

2022

View full text Add to dashboard Cite

Age-related macular degeneration AMD is one of the leading causes of blindness in the elderly population. An advanced form of AMD known as neovascular AMD (nAMD) is implicated as the main attributor of visual loss among these patients. The hallmark feature of nAMD is the presence of neovascular structures known as choroidal neovascular membranes (CNVs), along with fluid exudation, hemorrhages, and subretinal fibrosis. These pathological changes eventually result in anatomical and visual loss. A type of proangiogenic factor known as vascular endothelial growth factor (VEGF) has been known to mediate the pathological process behind nAMD. Therefore, therapy has transitioned over the years from laser therapy that ablates the lesions to using Anti-VEGF to target the pathology directly. In this work, we provide an overview of current and emerging therapies for the treatment of nAMD. Currently approved Anti-VEGF agents include ranibizumab, aflibercept, and brolucizumab. Bevacizumab, also an Anti-VEGF agent, is used to manage nAMD even though this is an off-label use. While Anti-VEGF agents have provided a favorable prognosis for nAMD, they are associated with a substantial financial burden for patients and the healthcare system, due to their high cost as well as the need for frequent repeat treatments and visits. Emerging therapies and studies aim to extend the intervals between required treatments and introduce new treatment modalities that would improve patients’ compliance and provide superior results.

show abstract

“…Again, this phenomenon may be explained in the context of increased injections leading to maintenance of adequate inhibition of VEGF, which in turn, inhibits vessel growth and increases the time for neovascular vessel proliferation cycles. While some studies demonstrate that the PRN method has fewer injections than TAE/TES dosing at a 1-year endpoint, they have similar number of visits, with poorer visual outcomes [64].…”

Section: Potential Mechanisms Of Management Strategies For Disease Anmentioning

confidence: 99%

Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration

Chaili¹,

Adrean²

2020

Visual Impairment and Blindness - What We Know and What We Have to Know

View full text Add to dashboard Cite

The purpose of this chapter is to examine the various treatment strategies used to manage neovascular age-related macular degeneration (nAMD). The chapter will focus on the three main strategies including fixed interval dosing, as needed Pro-Re-Nata (PRN) treatment and Treat-and-Extend (TAE), with its variant the Treat-Extend-Stop (TES) protocol. We will discuss the visual results of randomized clinical trials and retrospective studies using these methodologies and compare their outcomes, the pros and cons of each treatment strategy, as well as the underlying mechanisms that may explain these differences. The results of long-term extension trials following landmark randomized clinical studies and other long-term retrospective studies will also be compared to studies using a fixed interval dosing or the TAE/ TES method. We will also focus on the visual results of the TES protocol and examine recurrence rates, proposing a definition of the recurrence of choroidal neovascularization (CNV) versus increased disease activity. These topics discussed will help optimize anti-VEGF treatment regimens for patients with nAMD over the long term.

show abstract

A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD

Cited by 15 publications

References 22 publications

Management of neovascular Age-related macular degeneration: A review on landmark randomized controlled trials

Management of neovascular Age-related macular degeneration: A review on landmark randomized controlled trials

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration

Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration

Contact Info

Product

Resources

About